ClinicalTrials.gg
Not yet recruitingNCT05494723Updated Dec 23, 2025

Safety and Efficacy of YB-1113 in Treatment of POI

A Phase 1 interventional study of YB-1113 in POI, sponsored by Bright Cell, Inc.. Not yet recruiting. Open to female participants aged 18 Years to 39 Years. Per ClinicalTrials.gov, last updated 2025-12-23.

Sponsored by Bright Cell, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Non-randomized
Ages
18 Years to 39 Years
Sex
Female
01

Study summary

This phase 1 study is to evaluate the safety and tolerability of YB-1113 administered via intravenous (IV) infusion in the treatment of premature ovarian insufficiency (POI).

02

Conditions studied

  • POI
03

In context

Lead sponsor

Bright Cell, Inc. is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 39 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Female, 18 to \<40 years old, who are seeking fertility or preservation of fertility
  2. Oligo/Amenorrhea for at least 4 months
  3. At least two menopausal FSH levels (≥ 25 IU/L) with 4 to 6 weeks interval.
  4. AMH levels ≤ 1.0 ng/mL (measured on day 2-5 of the menstrual period).
  5. Subjects who are generally healthy by laboratory tests (normal complete blood count (CBC), comprehensive metabolic panel (CMP), and urinalysis) at screening
  6. For subjects who had before, the duration of amenorrhea should be more than 3 months after discontinuation of the oral contraception pill (OCP) or more than 6 months after discontinuation of Depo Provera (or similar) therapies

Key Exclusion Criteria:

  1. 1. Primary amenorrhea or FSH ≥ 40 IU/L
  2. Presence of to pregnancy
  3. POI due to cytotoxic chemotherapy or radiation therapy
  4. Subjects with FMR1 premutation (fragile X syndrome), a BMP15 mutation or family history of POI
  5. Subjects under hormonal treatments including hormone replacement therapy (HRT) for osteoporosis, cardiovascular disease, or recalcitrant vasomotor symptomatology.
  6. less than 3 months for HRT.
  7. Subjects with a history of breast cancer or other estrogen responsive cancer.
  8. Subjects with existing malignant neoplasm, under active management for malignant neoplasm or under active surveillance for malignant neoplasm.
  9. Subjects with history of thromboembolic events such as pulmonary embolism, stroke, or ischemic heart disease
  10. Subjects with uncontrolled hypertension, kidney disease, liver disease, or polycystic ovary syndrome (PCOS)
  11. Subjects with endocrinopathies including Cushing's disease, thyroid disease, congenital adrenal hyperplasia and hyperprolactinemia.
  12. Subjects under active management for disease.
  13. Subjects with intra-uterine devices (IUDs).
  14. Subjects who are pregnant, breastfeeding, or whose urinary pregnancy test is positive before participation in the study.
  15. Subjects who are allergic to low-molecular-weight heparin sodium or human albumin.
  16. Subjects with polyglandular autoimmune disease or other conditions require chronic administration of higher than 30 mg/day of hydrocortisone or its equivalent
  17. Subjects with hereditary or acquirement coagulopathies, including but not limited to hemophilia, Von Willebrand disease, liver disease, Vitamin K deficiency, and disorders.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
6 participants (estimated)

Study arms

  • Experimental
    Low-dose

    Low-dose YB-1113

    Drug: YB-1113

  • Experimental
    High-dose

    High-dose YB-1113

    Drug: YB-1113

Interventions

  • Human umbilical cord tissue-derived mesenchymal stem cells (hUC-MSC)

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events (AE)

    Reported treatment-related AE and serious adverse events (SAE)

    Time frame: 52 weeks

Secondary outcomes

  1. Blood anti-Müllerian hormone (AMH) level

    Changes of AMH level from baseline

    Time frame: 2, 6, 12, 24, and 52 weeks

  2. Follicle-stimulating hormone (FSH) and estradiol (E2) levels

    Changes of FSH and E2 from baseline

    Time frame: 2, 6, 12, 24, and 52 weeks

  3. Antral follicle counts (AFC)

    Changes of AFC numbers from baseline

    Time frame: 2, 6, 12, 24, and 52 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Jan 2028, 13 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2022
First posted
Aug 10, 2022
StartEst.
Dec 9, 2026
Primary completionEst.
Jan 9, 2028
CompletionEst.
Apr 9, 2028
Last update
Dec 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05494723
Lead sponsor
Bright Cell, Inc.
Responsible party
Sponsor
First posted
Aug 10, 2022
Start date
Dec 9, 2026 (estimated)
Primary completion
Jan 9, 2028 (estimated)
Completion
Apr 9, 2028 (estimated)
Last update
Dec 23, 2025

Study contacts

Jennifer Wang
Contact
jenniferw@brightcellinc.com
949-333-3636

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Solizmestrocel

Start the discussion